文献速递间质性肺疾病

针对肺纤维化焦虑的数字疗法:去中心化随机对照试验

A digital therapy targeting anxiety in pulmonary fibrosis: A decentralized randomized controlled trial.
PubMed 文献 · Respirology · 2024-12-03

COMPANION 研究在美国开展,纳入影像确诊肺纤维化且 GAD-7≥5 的患者 108 例,1:1 随机分为 Almee 数字认知行为疗法组与常规治疗组,干预 9 周。第 9 周 Almee 组 GAD-7 平均改善 1.8 分,对照组恶化 0.9 分,组间差异 2.7 分(95%CI 1.2-4.2,p=0.0006)。Almee 耐受良好,对肺纤维化相关焦虑有临床意义改善。

要点

  • Almee 数字认知行为疗法可改善肺纤维化患者焦虑,9 周 GAD-7 组间差异 2.7 分。
  • 研究为去中心化、开放标签、部分评估者盲法随机对照试验,108 例完成意向性分析。
  • Almee 耐受良好,可作为肺纤维化心理负担的个体化干预选择。

核心结论

  • Almee 数字认知行为疗法耐受良好,对肺纤维化相关焦虑显示有临床意义的改善。
  • Almee 有望成为管理肺纤维化患者心理负担的个体化干预手段。

研究设计与样本

  • COMPANION 为在美国开展的去中心化、随机、对照、开放标签、部分评估者盲法临床试验。
  • 纳入影像确诊肺纤维化且 GAD-7 评分≥5(范围 0-21)的患者,1:1 随机分为 Almee 组与常规治疗组,干预 9 周,按焦虑严重程度区组分层。
  • 主要终点为基线至第 9 周 GAD-7 评分变化。

主要发现

  • 第 9 周 Almee 组(n=54)GAD-7 平均改善 1.8 分(SEM=2.1)。
  • 第 9 周常规治疗组(n=54)GAD-7 平均恶化 0.9 分(SEM=2.2)。
  • 组间差异为 2.7 分(95%CI 1.2-4.2,p=0.0006)。

临床怎么用

  • 对肺纤维化合并焦虑(GAD-7≥5)患者,可考虑 Almee 数字认知行为疗法作为辅助心理干预。
  • 干预周期 9 周,以 GAD-7 评分变化评估疗效。

局限性

  • 研究为开放标签设计,仅部分评估者盲法。
  • 每组 46 例完成研究,存在失访。
  • 研究在美国开展,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pulmonary fibrosis, a manifestation of interstitial lung disease, is frequently associated with anxiety. The objective of this study, COMPANION, was to assess the anxiolytic efficacy of Almee, a digital cognitive behavioural therapy for patients with pulmonary fibrosis, compared to treatment as usual. METHODS: COMPANION was a randomized, controlled, open-label and partly reader-blinded, decentralized, clinical trial conducted in the United States. Eligible patients had radiology-confirmed pulmonary fibrosis and a Generalized Anxiety Disorder 7-item (GAD-7) score of ≥5 (possible range 0-21). Participants were randomized 1:1 to Almee or no intervention for 9 weeks, with block stratification by anxiety severity. The primary endpoint was change in GAD-7 score from baseline to week 9. Between 20 December 2022 and 14 August 2023, 108 participants were randomized, 54 to Almee and 54 to treatment as usual. RESULTS: In each arm, 46 participants completed the study; 108 cases were analysed as intention-to-treat. By week 9, average GAD-7 score had improved by 1.8 points (SEM = 2.1) in the Almee group (n = 54) and deteriorated by 0.9 points (SEM = 2.2) in the control group (n = 54), a 2.7-point difference (95% confidence interval: 1.2-4.2, p = 0.0006). CONCLUSION: Treatment with Almee was well-tolerated and showed clinically meaningful improvement in pulmonary fibrosis-related anxiety. Almee shows promise as a personalized intervention for management of the psychological burden related to living with pulmonary fibrosis.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Solomon JJ, Hallowell RW, Ganslandt C, et al. A digital therapy targeting anxiety in pulmonary fibrosis: A decentralized randomized controlled trial. Respirology. 2024. PMID: 39627155. doi:10.1111/resp.14859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。